Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Brucellosis Vaccine Market
Brucellosis Vaccine Market Size
- Report ID: GMI9544
- Published Date: May 2024
- Report Format: PDF
Brucellosis Vaccine Market Size
Brucellosis Vaccine Market size in 2023 accounted for USD 242.4 million and is projected to grow at CAGR of 4.9% between 2024 and 2032. One of the major drivers is the increasing prevalence of brucellosis in livestock, leading to significant economic losses in the agricultural sector.
Additionally, the rising awareness about the importance of vaccination among farmers and veterinarians is boosting the demand for brucellosis vaccines. Government initiatives and programs aimed at controlling and eradicating brucellosis are also fueling market growth. Furthermore, advancements in vaccine development technologies, such as recombinant DNA technology are expected to drive innovation in the brucellosis vaccine market, leading to the development of more effective and safer vaccines, thereby boosting the market growth.
Brucellosis vaccine is a type of animal vaccines developed to prevent brucellosis, a bacterial infection caused by various species of Brucella bacteria, including Brucella abortus, Brucella melitensis, and Brucella suis. These vaccines are primarily used in veterinary medicine to protect livestock, such as cattle, goats, sheep, and pigs, from contracting the disease.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Brucellosis Vaccine Market Size in 2023: | USD 242.4 Million |
| Forecast Period: | 2024 to 2032 |
| Forecast Period 2024 to 2032 CAGR: | 4.9% |
| 2032 Value Projection: | USD 370.7 Million |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 154 |
| Tables, Charts & Figures: | 274 |
| Segments covered: | Type, Vaccines, Animal type, End-user, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Brucellosis Vaccine Market Scope
